New Spike in COVID Infections, 1M+ Death Toll, Und
Post# of 111
(Total Views: 205)
Posted On: 06/10/2022 4:52:52 PM
New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies
- Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection
- Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerability
- While immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemic
- Health officials also recently acknowledged evidence that COVID-related deaths have now exceeded 1 million in the United States alone, making the country’s total the highest in the world
Johns Hopkins University announced in May that COVID-19-related deaths in the United States had surpassed 1 million just over two years after the outbreak of the worldwide pandemic, the highest recorded national death toll from COVID, while media reports acknowledged that the difficulty of precisely tracking COVID infections means the 1 million mark may have been passed “days or months earlier” (https://nnw.fm/oePcy ).
While local communities nationwide have mostly seen falling COVID infections rates during the warming climate and residents have been further encouraged by vaccination campaigns to enjoy public activities (https://nnw.fm/ir7iH ), President Joe Biden urged Americans “not to grow numb to such sorrow” associated with the virus’ death toll.
Senior U.S. health officials resumed their COVID-19 press conference events as daily average reports of new infections rose 25 percent in mid-May to more than 94,000 and continued upward within days to about 103,000 as of May 24, 2022. (https://nnw.fm/K1Ajs ).
“We have more than 200 million Americans vaccinated, more than 100 million Americans boosted. We have a pretty high degree of immunity in our population. But we’re also seeing at this moment a lot of infections across the country,” White House Covid-19 response coordinator Dr. Ashish Jha said during the press conference (https://nnw.fm/7HhxR ). “What is primarily driving that is these incredibly contagious sub variants. … They are more contagious with more immune escape and … that is a huge challenge.”
Biotech innovation company Aditxt (NASDAQ: ADTX) is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection.
Aditxt’s first commercial product is an immune monitoring technology trademarked as AditxtScore(TM) for COVID-19, which is designed to provide users with a personalized profile of their immune status — specifically in relation to their vulnerability and immune response regarding COVID’s SARS-CoV-2 virus and its known variants.
The immune system profile gives patients and their medical providers data regarding COVID they can use to develop informed health decisions, and the technology is supported by the company’s AditxtScore(TM) immune monitoring center in Richmond, Va.
For more information, visit the company’s website at www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://nnw.fm/ADTX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection
- Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerability
- While immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemic
- Health officials also recently acknowledged evidence that COVID-related deaths have now exceeded 1 million in the United States alone, making the country’s total the highest in the world
Johns Hopkins University announced in May that COVID-19-related deaths in the United States had surpassed 1 million just over two years after the outbreak of the worldwide pandemic, the highest recorded national death toll from COVID, while media reports acknowledged that the difficulty of precisely tracking COVID infections means the 1 million mark may have been passed “days or months earlier” (https://nnw.fm/oePcy ).
While local communities nationwide have mostly seen falling COVID infections rates during the warming climate and residents have been further encouraged by vaccination campaigns to enjoy public activities (https://nnw.fm/ir7iH ), President Joe Biden urged Americans “not to grow numb to such sorrow” associated with the virus’ death toll.
Senior U.S. health officials resumed their COVID-19 press conference events as daily average reports of new infections rose 25 percent in mid-May to more than 94,000 and continued upward within days to about 103,000 as of May 24, 2022. (https://nnw.fm/K1Ajs ).
“We have more than 200 million Americans vaccinated, more than 100 million Americans boosted. We have a pretty high degree of immunity in our population. But we’re also seeing at this moment a lot of infections across the country,” White House Covid-19 response coordinator Dr. Ashish Jha said during the press conference (https://nnw.fm/7HhxR ). “What is primarily driving that is these incredibly contagious sub variants. … They are more contagious with more immune escape and … that is a huge challenge.”
Biotech innovation company Aditxt (NASDAQ: ADTX) is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection.
Aditxt’s first commercial product is an immune monitoring technology trademarked as AditxtScore(TM) for COVID-19, which is designed to provide users with a personalized profile of their immune status — specifically in relation to their vulnerability and immune response regarding COVID’s SARS-CoV-2 virus and its known variants.
The immune system profile gives patients and their medical providers data regarding COVID they can use to develop informed health decisions, and the technology is supported by the company’s AditxtScore(TM) immune monitoring center in Richmond, Va.
For more information, visit the company’s website at www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://nnw.fm/ADTX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼